Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Recent & Breaking News (NDAQ:SAVA)

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava Sciences

Newsfile March 27, 2024

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA

PR Newswire March 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

PR Newswire March 27, 2024

TUESDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 27, 2024

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!

Accesswire March 27, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 27, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Newsfile March 26, 2024

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA

Newsfile March 26, 2024

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 26, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 26, 2024

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!

Accesswire March 26, 2024

UPCOMING DEADLINE ALERT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

Accesswire March 25, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Newsfile March 25, 2024

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

GlobeNewswire March 25, 2024

APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 25, 2024

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!

Accesswire March 25, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Newsfile March 24, 2024

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 24, 2024

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!

Accesswire March 24, 2024